Paul Lizzul F.'s Insider Trades & SAST Disclosures
Paul Lizzul F.'s most recent trade in AnaptysBio Inc was a trade of 97,200 Stock Option (right to buy) done . Disclosure was reported to the exchange on Jan. 3, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Paul Lizzul F..To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 97,200 | 97,200 | - | - | Stock Option (right to buy) | |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 34,100 | 34,100 | - | - | Restricted Stock Unit | |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 10,555 | 31,665 | - | - | Restricted Stock Unit | |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 10,555 | 26,095 (0%) | 0% | - | Common Stock | |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 6,145 | 12,290 | - | - | Restricted Stock Unit | |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 6,145 | 27,904 (0%) | 0% | - | Common Stock | |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.60 per share. | 03 Jan 2025 | 4,336 | 21,759 (0%) | 0% | 14.6 | 63,306 | Common Stock |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.30 per share. | 03 Jan 2025 | 2,261 | 25,643 (0%) | 0% | 15.3 | 34,593 | Common Stock |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 38.67 per share. | 23 Sep 2024 | 1,500 | 15,398 (0%) | 0% | 38.7 | 58,005 | Common Stock |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.50 per share. | 23 Sep 2024 | 1,500 | 16,898 (0%) | 0% | 18.5 | 27,750 | Common Stock |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Sep 2024 | 1,500 | 85,000 | - | - | Common | |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2024 | 6,000 | 0 | - | - | Restricted Stock Unit | |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2024 | 6,000 | 17,618 (0%) | 0% | - | Common Stock | |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 38.93 per share. | 14 Sep 2024 | 2,220 | 15,398 (0%) | 0% | 38.9 | 86,425 | Common Stock |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.50 per share. | 14 Aug 2024 | 2,000 | 13,618 (0%) | 0% | 18.5 | 37,000 | Common Stock |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Aug 2024 | 2,000 | 86,500 | - | - | Common | |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 40.00 per share. | 14 Aug 2024 | 2,000 | 11,618 (0%) | 0% | 40 | 80,000 | Common Stock |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jul 2024 | 50,000 | 50,000 | - | - | Common Stock | |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 35.00 per share. | 18 Jul 2024 | 1,500 | 11,618 (0%) | 0% | 35 | 52,500 | Common Stock |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jul 2024 | 1,500 | 88,500 | - | - | Common | |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.50 per share. | 18 Jul 2024 | 1,500 | 13,118 (0%) | 0% | 18.5 | 27,750 | Common Stock |
| AnaptysBio Inc | Lizzul F. Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2024 | 6,145 | 18,435 | - | - | Restricted Stock Unit | |
| AnaptysBio Inc | Lizzul Paul F. | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2024 | 6,145 | 12,672 (0%) | 0% | 0 | Common Stock | |
| AnaptysBio Inc | Paul Lizzul F. | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 21.81 per share. | 06 Jan 2024 | 2,554 | 10,118 (0%) | 0% | 21.8 | 55,703 | Common Stock |
| AnaptysBio Inc | Lizzul Paul F. | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2024 | 115,540 | 115,540 | - | - | Stock Option (right to buy) | |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2024 | 42,220 | 42,220 | - | - | Restricted Stock Unit | |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2023 | 67,070 | 67,070 | - | - | Stock Option (right to buy) | |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2023 | 24,580 | 24,580 | - | - | Restricted Stock Unit | |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2022 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 70,000 | 70,000 | - | - | Stock Option (right to buy) | |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 22.03 per share. | 15 Nov 2021 | 964 | 964 (0%) | 0% | 22.0 | 21,237 | Common Stock |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2021 | 45,000 | 45,000 | - | - | Stock Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges